Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2011

View Archived Issues

Phase III data on rivaroxaban in subjects with acute coronary syndromes

Human monoclonal antibodies show anticancer potential in preclinical and clinical settings

TMED10 gene SNP linked to Alzheimer's disease

Patrys raises funds to support anticancer pipeline

Medicis completes acquisition

U3-1287 combinations assessed in lung and pharynx cancer

Kowa identifies new cholesterol ester transfer protein inhibitors

New triterpenoid derivatives prepared by Concert Pharmaceuticals

Purdue exercises option to commercialize Intermezzo

Novel GPR119 receptor agonists disclosed by Bristol-Myers Squibb

Infinity Pharmaceuticals patents novel fatty acid synthase inhibitors

Zalicus begins phase I study of new Z-160 formulation

Spectrum Pharmaceuticals files IND with FDA for phosphate-binding agent

Scientists at Merck & Co. synthesize new fatty-acid amide hydrolase inhibitors

Belgian university discloses novel Amaryllidaceae isocarbostyryl derivatives for cancer

New 11-beta-HSD1 inhibitors patented in Korea

Targacept launches two new clinical studies of TC-5619

Pfizer finalizes acquisition

AtheroNova and Maxwell Biotech ratify agreement for AHRO-001

Oncolytics Biotech reports on Reolysin in pancreatic cancer

Achillion discloses preliminary proof-of-concept data on ACH-2928 and advances ACH-3102

Pivotal trial of cobicistat meets primary endpoint

ViroPharma and Halozyme report topline data from hereditary angioedema study

Second milestone reached in GenVec/Novartis collaboration

FDA accepts Cell Therapeutics' resubmission of pixantrone NDA as complete

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....